Respiratory Syncytial Virus Infections Clinical Trials

179 clinical trials for Respiratory Syncytial Virus Infections across international registries, including 10 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease — RECRUITING · PHASE2
• A Study of BLB-201 RSV Vaccine in Infants and Children — RECRUITING · PHASE1
• Human Interferon α1b Inhalation Solution Against Respiratory Syncytial Virus in Children With Lower Respiratory Tract Infections — RECRUITING · PHASE3
• A Study of Ziresovir (AK0529) in High-risk Adult With Respiratory Syncytial Virus (RSV) Infection. — RECRUITING · PHASE2
• Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV) — RECRUITING · PHASE1
• Clinical Trial of Recombinant RSV Vaccine (CHO Cell) (Adjuvanted) in Chinese Population Aged 18 Years and Older. — RECRUITING · PHASE1
• A Phase 2b, non-randomized, controlled, open-label, extension study to evaluate the persistence of immune response of the adjuvanted RSVPreF3 vaccine and the safety and immunogenicity following revaccination in lung and kidney transplant recipients (≥18 years of age) — RECRUITING · PHASE2
• Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children — RECRUITING · PHASE3
• Genotype and Disease Burden of RSV in Older Vietnamese Adults (RSV: Respiratory Syncytial Virus ) — RECRUITING
• Identification and Clinical Validation of Biomarkers Associated With Clinical Severity in Adults Infected With RSV — RECRUITING
• Effectiveness of Immunization in Preventing Severe Acute Respiratory Infection RSV in Children Under 6 Months in Bogotá — ACTIVE_NOT_RECRUITING
• A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease — ACTIVE_NOT_RECRUITING · PHASE3
• A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years — COMPLETED · PHASE1
• A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant — ACTIVE_NOT_RECRUITING · PHASE2
• An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study — ACTIVE_NOT_RECRUITING · PHASE3
• Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children — TERMINATED · PHASE1
• Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above — ACTIVE_NOT_RECRUITING · PHASE3
• Evaluating the Benefits of RSV Maternal Vaccination Using a Scottish National Dataset — NOT_YET_RECRUITING
• A Study in India on the Immune Response and Safety of a Respiratory Syncytial Virus (RSV) Older Adults (OA) Vaccine When Given to Older Adults 60 Years of Age and Above and Adults 50-59 Years of Age at Increased Risk (AIR) of Respiratory Syncytial Virus Lower Respiratory Tract Disease (RSV-LRTD) — COMPLETED · PHASE3
• Anti-RSV Study in Chinese Patients (ASCENT) — TERMINATED · PHASE2
• A phase 3b, randomized, open label, multi-country, multi-center, extension and crossover vaccination study to evaluate the immunogenicity and safety of different revaccination schedules and persistence of a single dose of the RSVPreF3 OA vaccine in adults aged 60 years and above who participated in the RSV OA=ADJ-006 study — TERMINATED · PHASE3
• Evaluation of Performance of the LumiraDx Influenza A/B + RSV Test at POC Testing Sites — COMPLETED · NA
• A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above — COMPLETED · PHASE2
• A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and Older — COMPLETED · PHASE3
• Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in Infants and Children — COMPLETED · PHASE1
• RSV Vaccine in Transplant Recipients — ACTIVE_NOT_RECRUITING · PHASE3
• A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab — COMPLETED · PHASE3
• A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adults — NOT_YET_RECRUITING · PHASE1
• A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adult Aged 18 Years and Above — ACTIVE_NOT_RECRUITING · PHASE1
• A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control — COMPLETED · PHASE3
• A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants — COMPLETED · PHASE2
• A Sudy to Evaluate the Efficacy and Safety of TNM001 in High-risk Infants — COMPLETED · PHASE3
• A phase 3, randomized, open-label, multi-country study to evaluate the immunogenicity, safety, reactogenicity and persistence of a single dose of the RSVPreF3 OA investigational vaccine and different revaccination schedules in adults aged 60 years and above. — TERMINATED · PHASE3
• A study on the safety of and immune response to different doses of an mRNA vaccine against RSV in healthy adults. — OTHER · PHASE1
• A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and Children With Pneumonia Caused by RSV — TERMINATED · PHASE1
• A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above — COMPLETED · PHASE3
• A Phase 3, randomized, controlled, partially blind, immuno-bridging study to evaluate immunogenicity, reactogenicity, safety and the occurrence of RSV-associated respiratory tract illness after administration of a single dose of GSK’s RSVPreF3 OA investigational vaccine in adults aged 60 years and older. — OTHER · PHASE3
• A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above — COMPLETED · PHASE3
• A Study to Learn About the Effects of Multiple Doses of Sisunatovir on People With Respiratory Syncytial Virus (RSV) Infection — COMPLETED · PHASE2
• Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above — COMPLETED · PHASE3
• Phase I, First-In Human Study to Evaluate Safety and Tolerability of EuRSV in Healthy Adults Aged Between 19 Years and 80 Years — ACTIVE_NOT_RECRUITING · PHASE1
• RSV Antibiotic Drivers And Resource-use — COMPLETED
• Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults — COMPLETED · PHASE3
• A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization — COMPLETED · PHASE3
• A Study of AK0529 in Adults Patients Hospitalized With RSV Infection — COMPLETED · PHASE2
• A Study on the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers — TERMINATED · PHASE3
• A Phase 3, open-label, randomized, controlled study to evaluate the immune response, safety and reactogenicity of RSVPreF3 OA investigational vaccine when co-administered with a COVID-19 mRNA vaccine (Omicron XBB.1.5) in adults aged 50 years and above. — OTHER · PHASE3
• A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults — COMPLETED · PHASE3
• A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above — COMPLETED · PHASE3
• A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers — TERMINATED · PHASE3

Refine this search